

Monash University and ClinChoice partner to accelerate clinical development of innovative therapies

March 23, 2026 | News

Sharing a clear commitment to improving health and wellbeing for patients around the world



Australia-based Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, have announced a strategic partnership designed to fast-track early-phase clinical trials and bring groundbreaking health innovations and discoveries closer to patients worldwide.

The collaboration combines Monash University's internationally recognised research excellence and clinical ecosystem with ClinChoice's global development, regulatory and data science capabilities to support high-quality, patient-centric research across Australia and the broader international research landscape. A particular focus will be on accelerating early-phase clinical development and bringing innovative therapies to patients faster.

Monash University is a part of Australia's largest clinical trial network, spanning five major affiliated health services with more than 7,000 hospital beds and a national network of more than 3,000 GPs. Monash University-led trials account for around a quarter of all clinical trial activity in Australia, reaching a patient population of 4.5 million people.

"By combining our global development experience with Monash's research excellence, we will advance clinical research in an even more efficient and impactful manner, ultimately bringing new therapies to patients faster," added Kerry Dyson, President, International Clinical Operations at ClinChoice.

Image caption- Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise) (left), Kevin Xu, Chairman and CEO of ClinChoice (center), and Kerry Dyson, President, International Clinical Operations at ClinChoice (right)